“LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel
TOKYO and CAMBRIDGE, Mass., July 12, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD…
Read More
0
